BRIEF published on 02/12/2026 at 07:35, 4 months 17 days ago Nicox maintains its PEA-PME status for 2026 PEA-PME Euronext Growth Paris Investment Ophthalmology Nicox
BRIEF published on 02/10/2026 at 07:35, 4 months 19 days ago Nicox to Present Key Data at AGS Annual Meeting 2026 Clinical Trials Glaucoma Nicox NCX 470 AGS 2026
PRESS RELEASE published on 02/10/2026 at 07:30, 4 months 19 days ago Nicox to Present Data from NCX 470 Phase 3 Studies at American Glaucoma Society (AGS) Annual Meeting 2026 Nicox to present NCX 470 Phase 3 data at AGS Annual Meeting 2026 with podium presentations showcasing clinical study results and efficacy of the ophthalmic solution Clinical Study Ophthalmology Nicox NCX 470 AGS Annual Meeting 2026
BRIEF published on 01/20/2026 at 07:35, 5 months 12 days ago Nicox announces its participation in several congresses in 2026 Glaucoma Ophthalmology Nicox NCX 470 Congress 2026
BRIEF published on 01/20/2026 at 07:35, 5 months 12 days ago Nicox Announces 2026 Conference Participation and Data Presentations Scientific Data Ophthalmology NCX 470 Conference Participation 2026 Events
PRESS RELEASE published on 01/20/2026 at 07:30, 5 months 12 days ago Nicox Announces Conference Attendance in H1 2026 and Upcoming Scientific Data Presentations Nicox to attend key ophthalmology conferences and present scientific data at AGS 2026 Annual Meeting. Management team available for meetings. Developing innovative eye health solutions Conference Scientific Data Ophthalmology Nicox Eye Health
BRIEF published on 12/16/2025 at 07:35, 6 months 16 days ago Nicox Finalizes Key Data for NCX 470 NDA Submission by H1 2026 Clinical Trials Ophthalmology Nicox NCX 470 NDA Submission
PRESS RELEASE published on 12/16/2025 at 07:30, 6 months 16 days ago Nicox Completes NCX 470 New Drug Application Key Data Generation for Submission as Planned in H1 2026 Nicox completes key data generation for NCX 470 new drug application submission in H1 2026, including clinical trial and stability data. U.S. and China submissions on track FDA Clinical Trials Nicox NCX 470 New Drug Application
BRIEF published on 10/23/2025 at 07:35, 8 months 9 days ago Nicox Releases First Half 2025 Financial Results Financial Results Debt Repayment Ophthalmology Cost Control NCX 470
PRESS RELEASE published on 10/23/2025 at 07:30, 8 months 9 days ago Nicox Provides First Half 2025 Financial Results Nicox provides first half 2025 financial results, expects NDA submissions for NCX 470 in 2026. Company aims to finance operations for 12 months and repay debts by 2026 Financial Results Debt Repayment Nicox NCX 470 NDA Submissions
Published on 07/01/2026 at 17:00, 12 hours 7 minutes ago Notification of Relevant Change to Significant Shareholder
Published on 07/01/2026 at 14:30, 14 hours 37 minutes ago AIAI Holdings' MediGuide Launches Digital Platform
Published on 07/01/2026 at 13:30, 15 hours 37 minutes ago Sidney Resources Corporation Appoints Former Idaho Governor C.L. "Butch" Otter as Chairman of the Board
Published on 07/01/2026 at 13:00, 16 hours 7 minutes ago Fox River Issues Shares Pursuant to Exploration Agreement in Connection with Impending Arrangement
Published on 07/01/2026 at 03:15, 1 day 1 hour ago GLG Life Tech Corporation Announces 2026 AGM Voting Results
Published on 07/01/2026 at 20:40, 8 hours 27 minutes ago KNDS to resume its Initial Public Offering process when Capital Markets conditions are supportive
Published on 07/01/2026 at 20:04, 9 hours 2 minutes ago 2CRSi SA: 2CRSi initiates an independent verification procedure regarding its German contract.
Published on 07/01/2026 at 19:00, 10 hours 7 minutes ago OLB strengthens its leadership team to drive the next phase of growth
Published on 07/01/2026 at 18:55, 10 hours 12 minutes ago OLB Ensures Leadership Continuity Following Management Board Changes / Christophe Jéhan assumes responsibilities for Marc Ampaw’s business areas on interim basis
Published on 07/01/2026 at 18:29, 10 hours 38 minutes ago Aperam Update on Q2 2026 market & financial trends
Published on 07/01/2026 at 18:26, 10 hours 41 minutes ago Modula renews its confidence in AMA with a four-year agreement integrating XpertEye’s new AI-powered features
Published on 07/01/2026 at 17:54, 11 hours 12 minutes ago TF1 - Monthly disclosure of the total number of shares and voting rights - June 2026
Published on 07/01/2026 at 17:45, 11 hours 22 minutes ago Availability of the Pre-H1 2026 Results Communication
Published on 07/01/2026 at 17:40, 11 hours 27 minutes ago Report on share repurchases from 24 to 30 June 2026
Published on 07/01/2026 at 17:35, 11 hours 32 minutes ago Disclosure of transactions in own shares from June 29 to June 30, 2026
